Christine Baudelet

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Julie R. Brahmer, Karen L. Reckamp, Paul Baas et al. · New England Journal of Medicine · 2015 · 8.4K citations · Full text

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Naiyer A. Rizvi, Julien Mazières, David Planchard et al. · The Lancet Oncology · 2015 · 1.4K citations · Full text

Checkmate 063, Single-arm Trial, Medicine +8

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Paul Baas, Arnaud Scherpereel, Anna K. Nowak et al. · The Lancet · 2021 · 1.1K citations · Full text

Checkmate 743, Medicine, Pathology +4

Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial

Yi‐Long Wu, Shun Lü, Ying Cheng et al. · Journal of Thoracic Oncology · 2019 · 347 citations

Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆

David R. Spigel, David Vicente, Tudor–Eliade Ciuleanu et al. · Annals of Oncology · 2021 · 263 citations · Full text